Science has always been a grind. Hypothesize, test, fail, repeat until someone finally stumbles across something worth publishing. Lila Sciences decided that sounded like a job for machines. Not just any machines, but a full-blown “scientific superintelligence” that doesn’t get tired, doesn’t forget, and doesn’t need peer review to validate its existence. Founded in 2023 by Noubar Afeyan, Geoffrey von Maltzahn, Molly Gibson, Jacob Feala, Alexandra Sneider, and Ben Kompa, the company emerged from Flagship Pioneering’s labs and now calls Cambridge home. In under two years, they’ve gone from idea to unicorn with the kind of momentum that doesn’t happen by accident.
The latest move: a $235 million Series A. That’s not seed money, that’s institution-shaking capital. Co-led by Braidwell and Collective Global, the round drew in Altitude Life Science Ventures, Alumni Ventures, ARK Venture Fund, Common Metal, General Catalyst, March Capital, The Mathers Foundation, Modi Ventures, NGS Super, the State of Michigan Retirement System, a wholly owned subsidiary of the Abu Dhabi Investment Authority, and Flagship Pioneering. Add that to a $200 million seed raise earlier this year, and total funding sits at $435 million with a valuation of $1.23 billion. Fast math: Lila Sciences didn’t crawl into unicorn territory, it sprinted.
Inside the Cambridge AI Science Factory, they’ve already run hundreds of thousands of experiments, producing genetic medicine constructs that beat today’s commercial therapeutics, hundreds of antibodies and peptides for new targets, non-platinum catalysts for green hydrogen, and carbon capture sorbents that outperform market leaders. They’re not just dabbling across disciplines, they’re accelerating discovery across life sciences, chemistry, and materials science with a system that never sleeps.
Here’s the differentiator. Lila Sciences isn’t using AI as a sidekick. The platform is a closed loop: large language models parse scientific literature, generative models spin out biomolecules and materials, robots execute experiments at scale, and results feed straight back into the models. Each cycle compounds knowledge, shrinking research timelines from years into days. That’s not iteration, that’s velocity science.
The leadership roster reads like a who’s who of next-gen science and execution. Geoffrey von Maltzahn runs point as CEO, with Molly Gibson advancing the science, Jacob Feala bringing computational depth, Alexandra Sneider driving corporate development, and Ben Kompa steering AI innovation. Add George Church as Chief Scientist, Andrew Beam as CTO, Jonathan Hennek as CPO, Christopher Fussell managing operations, Scott Robertson leading commercialization, Sue Kwon shaping communications, Jack Milwid pushing culture, Kenneth Stanley expanding open-endedness, Rafael Gómez-Bombarelli powering materials science, and Chris O’Donnell building business, the lineup has scale written all over it.
The new funding fuels expansion to Boston, San Francisco, and London, a doubling of headcount, and the opening of the platform to external partners by the end of 2025. They’re even setting up head-to-head trials: human researchers versus AI models. With $235 million fresh, the bet is clear. Lila Sciences isn’t tweaking the process of discovery. They’re running it on infinite repeat, and the rest of the world is about to see what happens when science finds its second engine.
